Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of infection in kidney transplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210216004

Enrollment

100

Registered

2021-02-16

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection in kidney transplant recipients CMV BK virus interferon elispot immunity immunocompromised

Interventions

KT recipients with low T-cell immunity,KT recipients with high T-cell immunity

Screening,Screening

Low T-cell immunity group,High T-cell immunity group

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: All kidney transplant recipients

Exclusion criteria

Exclusion criteria: Those who refused to join the study

Design outcomes

Primary

Measure	Time frame
Infection 6 months Plasma CMV viral load, plasma BKV viral load, etc.	—

Secondary

Measure	Time frame
Allograft rejection 6 months Creatinine, eGFR, DSA, allograft tissue pathology	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital

jackrapong.brm@mahidol.ac.th6622011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026